Lv1
48 积分 2025-01-06 加入
World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults
17天前
已完结
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
2个月前
已完结
Efficacy and safety of canagliflozin when used in conjunction with incretin‐mimetic therapy in patients with type 2 diabetes
2个月前
已完结
Glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta‐analysis
2个月前
已完结
Prevalence and Treatment of Diabetes in China, 2013-2018
2个月前
已完结
Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial
2个月前
已完结
The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis
2个月前
已完结
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy
2个月前
已完结
SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose‐lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review
2个月前
已完结
Global burden of atherosclerotic cardiovascular disease attributed to lifestyle and metabolic risks
2个月前
已完结
皖公网安备34019202002308
